Targeting Integrins with Radiolabeled RGD Analogues for Radiotheranostics of Metastatic Radioactive Iodine Nonresponsive Thyroid Cancer: New Avenues in Personalized Medicine
Restricted accessResearch articleFirst published online April, 2020
Targeting Integrins with Radiolabeled RGD Analogues for Radiotheranostics of Metastatic Radioactive Iodine Nonresponsive Thyroid Cancer: New Avenues in Personalized Medicine
LiuJ, YuanS, WangL, SunX, HuX, MengX, YuJ. 2019. Diagnostic and predictive value of using RGD PET/CT in patients with cancer: a systematic review and meta-analysis. Biomed Res Int, 2019:8534761.
2.
HamidiH, IvaskaJ. 2018. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer, 18:533–548.
3.
MasonWP. 2015. End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma. Neuro Oncol, 17:634–635.
4.
HoffmannS, MaschuwK, HassanI, ReckzehB, WunderlichA, LingelbachS, ZielkeA. 2005. Differential pattern of integrin receptor expression in differentiated and anaplastic thyroid cancer cell lines. Thyroid, 15:1011–1020.
5.
ChengW, FengF, MaC, WangH. 2016. The effect of antagonizing RGD-binding integrin activity in papillary thyroid cancer cell lines. Onco Targets Ther, 9:1415–1423.
6.
PariharAS, MittalBR, KumarR, ShuklaJ, BhattacharyaA. 2020. 68Ga-DOTA-RGD2 positron emission tomography/computed tomography in radioiodine refractory thyroid cancer: prospective comparison of diagnostic accuracy with 18F-FDG positron emission tomography/computed tomography and evaluation toward potential theranostics. Thyroid, 30:557–567.
7.
VatsaR, ShyklaJ, MittalBR, BhusariP, SoodA, BasherRK, BhattacharyaA. 2017. Usefulness of 68Ga-DOTA-RGD (alphavbeta3) PET/CT imaging in thyroglobulin elevation with negative iodine scintigraphy. Clin Nucl Med, 42:471–472.
8.
NiuG, ChenX. 2016. RGD PET: from lesion detection to therapy response monitoring. J Nucl Med, 57:501–502.
9.
ZhengK, LiangN, ZhangJ, LangL, ZhangW, LiS, ZhaoJ, NiuG, LiF, ZhuZ, ChenX. 2015. 68Ga-NOTA-PRGD2 PET/CT for integrin imaging in patients with lung cancer. J Nucl Med, 56:1823–1827.
ShaoG, GuW, GuoM, ZangS, FuJ, LiuS, WangF, WangZ. 2017. Clinical study of (99m)Tc-3P-RGD2 peptide imaging in osteolytic bone metastasis. Oncotarget, 8:75587–75596.
12.
ChenH, JacobsonO, NiuG, WeissID, KiesewetterDO, LiuY, MaY, WuH, ChenX. 2017. Novel “Add-On” molecule based on Evans blue confers superior pharmacokinetics and transforms drugs to theranostic agents. J Nucl Med, 58:590–597.
13.
ZhangJ, MaoF, NiuG, PengL, LangL, LiF, YingH, WuH, PanB, ZhuZ, ChenX. 2018. (68)Ga-BBN-RGD PET/CT for GRPR and integrin alphavbeta3 imaging in patients with breast cancer. Theranostics, 8:1121–1130.
14.
KimYI, YoonHJ, PaengJC, CheonGJ, LeeDS, ChungJK, KimEE, MoonWK, KangKW. 2016. Prognostic value of 68Ga-NOTA-RGD PET/CT for predicting disease-free survival for patients with breast cancer undergoing neoadjuvant chemotherapy and surgery: a comparison study with dynamic contrast enhanced MRI. Clin Nucl Med, 41:614–620.
